iBET

iBET receives the visit of Sanofi for Assessment of Ongoing Ventures

02.05.2019

Recently, iBET received the visit of Sanofi, a global healthcare leader with whom a strong partnership has been built along the past years. This visit was planned under the scope of ongoing collaborative projects, allowing Sanofi and iBET teams to discuss main achievements in the areas of gene therapy and mAbs development.  

This face-to-face meeting aim was to report the resultant progress to the Joint Steering Committee (JSC), which included Dr Hitto Kauffmann (Global Vice President Biopharmaceutics Development and Platform Innovation at Sanofi), Dr Francisco del Val (General Director of Sanofi Portugal), Professor Paula Alves (CEO of iBET) and Professor Manuel Carrondo (Vice-President of iBET). 

A special focus was given to the progress of the recently established Sanofi satellite laboratory at iBET, after accomplishment of the first milestones. Patrícia Gomes-Alves, head of the Sanofi satellite lab explains: “This face to face meeting was very important to revise projects´ milestones and specific goals. The feedback from JSC on the work performed by the team since August 2018 was very positive and new ideas on different research topics have already emerged”, reflecting the positive output of the Sanofi satellite lab after the first 8 months. 

In the area of gene therapy, the progress and major achievements of the R&D project coordinated by Ana Sofia Coroadinha from the Animal Cell Technology unit was also presented to the JSC and discussed with Sanofi.